WASHINGTON, DC—For patients who present with STEMI complicated by cardiogenic shock (STEMI-CS), it’s not news that the long-awaited DanGer Shock trial showed better 180-day survival after Impella CP ...
MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...
PARIS, France—Immediate multivessel PCI offers similar survival out to 180 days when compared with culprit-only PCI among STEMI patients with cardiogenic shock, according to provocative new data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback